Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Pharmacoeconomics and its implication on priority-setting for essential medicines in Tanzania: a systematic review.

Mori AT, Robberstad B.

BMC Med Inform Decis Mak. 2012 Sep 27;12:110. doi: 10.1186/1472-6947-12-110. Review.

2.

Cost-Effectiveness and Affordability of Interventions, Policies, and Platforms for the Prevention and Treatment of Mental, Neurological, and Substance Use Disorders.

Levin C, Chisholm D.

In: Patel V, Chisholm D, Dua T, Laxminarayan R, Medina-Mora ME, editors. Mental, Neurological, and Substance Use Disorders: Disease Control Priorities, Third Edition (Volume 4). Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2016 Mar 14. Chapter 12.

3.

Pharmaceutical policies: effects of financial incentives for prescribers.

Rashidian A, Omidvari AH, Vali Y, Sturm H, Oxman AD.

Cochrane Database Syst Rev. 2015 Aug 4;(8):CD006731. doi: 10.1002/14651858.CD006731.pub2. Review.

PMID:
26239041
4.
5.

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.

Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G.

Health Technol Assess. 2001;5(28):1-110. Review.

6.

Priority setting on malaria interventions in Tanzania: strategies and challenges to mitigate against the intolerable burden.

Makundi EA, Mboera LE, Malebo HM, Kitua AY.

Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):106-11. Review.

PMID:
18165481
7.

Pharmacoeconomics.

Ahuja J, Gupta M, Gupta AK, Kohli K.

Natl Med J India. 2004 Mar-Apr;17(2):80-3. Review.

PMID:
15141600
8.

Integrating prevention of mother-to-child HIV transmission (PMTCT) programmes with other health services for preventing HIV infection and improving HIV outcomes in developing countries.

Tudor Car L, van-Velthoven MH, Brusamento S, Elmoniry H, Car J, Majeed A, Atun R.

Cochrane Database Syst Rev. 2011 Jun 15;(6):CD008741. doi: 10.1002/14651858.CD008741.pub2. Review.

PMID:
21678382
9.

The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.

Achilla E, McCrone P.

Appl Health Econ Health Policy. 2013 Apr;11(2):95-106. doi: 10.1007/s40258-013-0016-2. Review.

PMID:
23494934
10.

Cost effectiveness of liraglutide in type II diabetes: a systematic review.

Zueger PM, Schultz NM, Lee TA.

Pharmacoeconomics. 2014 Nov;32(11):1079-91. doi: 10.1007/s40273-014-0192-4. Review.

PMID:
25052903
11.

Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review.

Ozawa S, Mirelman A, Stack ML, Walker DG, Levine OS.

Vaccine. 2012 Dec 17;31(1):96-108. doi: 10.1016/j.vaccine.2012.10.103. Epub 2012 Nov 8. Review.

PMID:
23142307
12.

Using Economic Evidence to Set Healthcare Priorities in Low-Income and Lower-Middle-Income Countries: A Systematic Review of Methodological Frameworks.

Wiseman V, Mitton C, Doyle-Waters MM, Drake T, Conteh L, Newall AT, Onwujekwe O, Jan S.

Health Econ. 2016 Feb;25 Suppl 1:140-61. doi: 10.1002/hec.3299. Review.

13.

Health economic research on vaccinations and immunisation practices--an introductory primer.

Szucs TD.

Vaccine. 2005 Mar 18;23(17-18):2095-103. Review.

PMID:
15755578
14.

Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.

Acosta A, Ciapponi A, Aaserud M, Vietto V, Austvoll-Dahlgren A, Kösters JP, Vacca C, Machado M, Diaz Ayala DH, Oxman AD.

Cochrane Database Syst Rev. 2014 Oct 16;(10):CD005979. doi: 10.1002/14651858.CD005979.pub2. Review.

PMID:
25318966
15.

Pharmacoeconomics--an aid to better decision-making.

Arenas-Guzman R, Tosti A, Hay R, Haneke E; National Institue for Clinical Excellence.

J Eur Acad Dermatol Venereol. 2005 Sep;19 Suppl 1:34-9.

PMID:
16120204
16.

A systematic review of economic evaluations of interventions to tackle cardiovascular disease in low- and middle-income countries.

Suhrcke M, Boluarte TA, Niessen L.

BMC Public Health. 2012 Jan 3;12:2. doi: 10.1186/1471-2458-12-2. Review.

17.

Economic evaluations of smoking cessation and relapse prevention programs for pregnant women: a systematic review.

Ruger JP, Emmons KM.

Value Health. 2008 Mar-Apr;11(2):180-90. Epub 2007 Sep 13. Review.

18.

Conquering the intolerable burden of malaria: what's new, what's needed: a summary.

Breman JG, Alilio MS, Mills A.

Am J Trop Med Hyg. 2004 Aug;71(2 Suppl):1-15. Review.

PMID:
15331814
19.

Centre-based day care for children younger than five years of age in low- and middle-income countries.

Brown TW, van Urk FC, Waller R, Mayo-Wilson E.

Cochrane Database Syst Rev. 2014 Sep 25;(9):CD010543. doi: 10.1002/14651858.CD010543.pub2. Review.

PMID:
25254354
20.

The state of health economic research in South Africa: a systematic review.

Gavaza P, Rascati KL, Oladapo AO, Khoza S.

Pharmacoeconomics. 2012 Oct 1;30(10):925-40. doi: 10.2165/11589450-000000000-00000. Review.

PMID:
22809450

Supplemental Content

Support Center